Fax: (713) 563-9586
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers†
A Gynecologic Oncology Group study
Article first published online: 4 FEB 2009
Copyright © 2009 American Cancer Society
Volume 115, Issue 7, pages 1395–1403, 1 April 2009
How to Cite
Tian, C., Markman, M., Zaino, R., Ozols, R. F., McGuire, W. P., Muggia, F. M., Rose, P. G., Spriggs, D. and Armstrong, D. K. (2009), CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers. Cancer, 115: 1395–1403. doi: 10.1002/cncr.24152
The following Gynecologic Oncology Group member institutions participated in the primary treatment studies: University of Alabama at Birmingham, Oregon Health Sciences University, Duke University Medical Center, Abington Memorial Hospital, University of Rochester Medical Center, Walter Reed Medical Center, Wayne State University, University of Minnesota Medical School, University of Southern California at Los Angeles, University of Mississippi Medical Center, Colorado Gynecologic Oncology Group, P.C., University of California at Los Angeles, University of Miami School of Medicine, Milton S. Hershey Medical Center, Georgetown University Hospital, University of Cincinnati, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Medical Center at Dallas, Indiana University Medical Center, Wake Forest University School of Medicine, Albany Medical Center, University of California Medical Center at Irvine, Tufts-New England Medical Center, Rush-Presbyterian-St. Luke's Medical Center, Stanford University Medical Center, SUNY Downstate Medical Center, University of Kentucky, Eastern Virginia Medical School, The Cleveland Clinic Foundation, Johns Hopkins Cancer Center, State University of New York at Stony Brook, Eastern Pennsylvania Gynecology/Oncology Center, P.C., Washington University School of Medicine, Cooper Hospital/University Medical Center, Columbus Cancer Council, M. D. Anderson Cancer Center, University of Massachusetts Medical School, Fox Chase Cancer Center, Medical University of South Carolina, Women's Cancer Center, University of Oklahoma.
- Issue published online: 19 MAR 2009
- Article first published online: 4 FEB 2009
- Manuscript Accepted: 29 SEP 2008
- Manuscript Revised: 23 SEP 2008
- Manuscript Received: 11 JUN 2008
- National Cancer Institute. Grant Numbers: CA 27,469 (Gynecologic Oncology Group), CA 37,517 (Gynecologic Oncology Group Statistical and Data Center)
- 11Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19: 1001-1007., , , et al.
- 15A phase III randomized trial of intravenous paclitaxel and cisplatin versus intravenous paclitaxel, intraperitoneal cisplatin and intraperitoneal paclitaxel in patients with optimal stage III epithelial ovarian carcinoma or primary peritoneal carcinoma. N Engl J Med. 2006; 354: 34-43., , , et al.
- 27Significance of pretreatment CA-125 level in advanced ovarian carcinoma: a meta-analysis of 7 Gynecologic Oncology Group protocols [abstract]. Gynecol Oncol. 2007; 104: S3., , , et al.